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INFLUENZA VACCINE GIVEN TO PREGNANT WOMEN REDUCES  
HOSPITALIZATION DUE TO INFLUENZA IN THEIR INFANTS 
 
Isaac Benowitz, Daina Esposito, Kristina Gracey, Eugene Shapiro, Marietta Vázquez. Sections of General 
Pediatrics and Infectious Diseases, Dept. of Pediatrics, Yale University School of Medicine, New Haven, CT. 
 
The aim of this study was to determine whether giving influenza vaccine to pregnant 
women can reduce the incidence of hospitalization due to influenza in their infants in the 
first year of life. This was a matched, hospital-based case-control study at Yale-New Haven 
Children’s Hospital. Case and control subjects were all aged <12 months at the time of their 
hospital admission from 2000 to 2009. All subjects were identified through hospital records. 
Cases were infants admitted due to influenza infection. Controls were infants who did not 
have influenza infection at the time of hospitalization, matched to cases by date of birth and 
date of hospitalization (both within 4 weeks before or after). We contacted parents of all 
subjects to collect information on the subjects’ health and home setting and to get 
permission to review subjects’ and mothers’ hospital records and outpatient medical 
records—this was used to determine whether the subject or mother had received influenza 
vaccine or other vaccines and to identify underlying health conditions that could predispose 
to severe influenza infection. Conditional logistic regression was used to determine the 
relative risk of hospitalization for influenza infection for mothers who did or did not receive 
influenza vaccine during pregnancy or other times. The mothers of 2 (2.2%) of 91 cases and 
31 (19.9%) of 156 controls aged <6 months and 1 (4.6%) of 22 cases and 2 (5.6%) of 36 
controls aged ≥6 months received influenza vaccine during pregnancy. The effectiveness of 
influenza vaccine given to mothers in pregnancy in preventing hospitalization in their 
infants aged <6 months, adjusted for potential confounders, was 91.5% (95% CI: 61.7%–
98.1%, p=0.001). Influenza vaccine given to pregnant women was 91.5% effective in 
preventing hospitalization of their infants due to influenza in the first six months of life.
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INTRODUCTION 
 
Influenza is the leading cause of vaccine-preventable death in the United States (CDC 
2003), where it is responsible for 200,000 hospitalizations and 36,000 deaths per year 
(Thompson 2004). The highest burden of disease is in young children, pregnant women, the 
elderly, and people with certain chronic medical conditions. In young children, the highest 
incidence of hospitalization attributable to influenza is in infants aged <1 year, with those 
aged <6 months at highest risk (Neuzil 2000). Rates of hospitalization of healthy infants for 
influenza are similar to the rates in high risk adults, and are even higher for infants with 
underlying chronic medical conditions, in particular respiratory conditions (Neuzil 2000). 
 
Influenza is a respiratory infection caused by the influenza virus that is transmitted through 
infected airborne droplets. Common symptoms of infection include fever, headache, 
fatigue, dry couch, sore throat, runny or stuff nose, muscle aches, and gastrointestinal upset. 
Complications of influenza leading to hospitalization or death can occur from direct effects 
of the virus, from exacerbations of pre-existing underlying or chronic medical conditions 
such as cardiopulmonary disease, or from causes related to pregnancy or young or old age. 
In infants, influenza can present with a sepsis-like picture that differs significantly from the 
classic presentation seen in adults. For example, infants may have fever but lack respiratory 
symptoms. Gastrointestinal symptoms (such as diarrhea) are another possible presentation. 
 
Influenza is seasonal in the northern hemisphere, predominantly circulating in the fall and 
winter months. It typically peaks in February or March, although it may peak as late as 
April or May. Influenza virus has circulated in humans for thousands of years; since 1977, 
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three influenza virus strains have circulated globally in the human population: A H1N1, A 
H3N2, and B. These and other strains also circulate in avian hosts and in other mammals. 
Minor strain variation (antigenic drift) occurs from season to season and is associated with 
reinfection. Major variation (antigenic shift) occurs less frequently and is associated with 
pandemics (Fiore 2009). 
 
In April 2009, a novel influenza strain appeared in the northern hemisphere that was similar 
to influenza strains that have circulated in swine in the past but was unlikely any one strain. 
This strain, 2009 influenza A H1N1, led to a pandemic with large numbers of people 
infected in many countries worldwide, leading to significant morbidity and mortality. 
 
Influenza vaccine 
 
Annual receipt of the influenza vaccine is currently the most effective method of preventing 
influenza infection in most individuals and this has been shown to reduce the burden of 
influenza infection. Two types of vaccine have been developed and are available 
commercially: an injectable, inactivated trivalent vaccine that can be used in any person 
aged ≥6 months, and a nasal, live-attenuated vaccine that can be used in non-pregnant, 
healthy persons aged 5–49 years. Either vaccine protects recipients against three influenza 
virus strains, one from each of the major groups. New influenza vaccine is produced yearly 
with the included strains selected several months prior to influenza season to allow for 
production, distribution, and administration. This vaccine is 70-90% effective in healthy 
adults in a year with good “strain match” between the vaccine strains and the circulating 
strains; effectiveness is lower in the elderly and in very young children and in years in 
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which there is poor “strain match.” Antiviral medications are also available for the 
prevention and treatment of influenza infection; however, these medications currently are 
not approved for use in persons aged <12 months (Fiore 2009). No vaccine is available for 
use in infants aged <6 months. 
 
Inactivated influenza vaccine is recommended by the Centers for Disease Control and 
Prevention (CDC) for all people except for infants aged <6 months (for whom the vaccine 
is poorly immunogenic) and persons with a serious allergy to eggs (Fiore 2009, Gruber 
1997). Although many influenza infections lead to only minor symptoms, more serious and 
life-threatening outcomes are also possible as described above. The recommendation for 
annual influenza vaccination is intended to reduce hospitalization and death. Strategies for 
the protection of groups who cannot receive influenza vaccine have included washing 
hands, avoiding contact with persons infected with influenza, and vaccination of close 
contacts (Fiore 2009). Both the CDC and the Advisory Committee for Immunization 
Practices recommend that household contacts of infants aged <6 months, along with their 
out-of-home caregivers, receive the influenza vaccine in order to form a “cocoon” of 
protection. However, the effectiveness of these strategies remains unknown. 
 
CDC and the American College of Obstetrics and Gynecology (ACOG) recommend all 
women who will be pregnant during the influenza season receive inactivated influenza 
vaccination (Fiore 2008). This recommendation is based on the elevated burden of 
influenza-related complications, hospitalization, and death in pregnant women seen during 
past influenza seasons and in particular during past influenza pandemics (Fiore 2009, 
Naleway 2006). In general, persons aged ≥6 months develop high titers of influenza 
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antibodies after vaccination and these antibodies are protective against illness, with the 
degree of protection related to the similarity between the strain of influenza in the vaccine 
and the strain of influenza circulating in the population at the time of infection. The 
antibody response in children at high risk for influenza-related complications might be 
lower than that of healthy children (Fiore 2009). 
 
Vaccination of pregnant women could provide protection to the infant early in life, and this 
suggests that a novel approach to protect young infants against influenza infection may be 
to vaccinate their mothers during pregnancy (Munoz 2001, GPVI 1996). Both animal and 
human studies support the possibility of protecting infants against influenza by immunizing 
the mother. Antibodies (immunoglobulin G) cross the placenta via active transport from the 
mother to the fetus in the final weeks of pregnancy (Kohler 1966, Hobbs 1967, Reuman 
1983, Mbawuike 1990). After birth, the infant may receive antibodies (immunoglobulin A) 
from the mother via breastmilk (Sweet 1987) and these may provide further protection. 
 
Review of the literature 
 
One study showed that children aged ≤12 months, included those with no previous health 
problems, were hospitalized at a rate comparable to that in elderly (Neuzil 2000). Neuzil et 
al. also showed that a significant number of annual deaths attributable to influenza infection 
occur in infants, and that young children may have a higher risk of influenza-associated 
complications and hospitalization compared with healthy older children and adults aged <65 
years (Fiore 2009). Complications of influenza infection include bacterial pneumonia, 
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dehydration, and worsening of chronic medical conditions such as congestive heart failure, 
asthma, and diabetes. 
 
Animal studies have shown that immunizing pregnant mice against influenza protected their 
offspring against severe influenza infection. Antibodies are transferred in breastmilk 
(immunoglobulin A) and across the placenta (immunoglobulin G) (Reuman 1983, 
Mbawuike 1990). In one study, pregnant mice received active influenza vaccine and their 
offspring were studied for the response to influenza infection. In another study, pregnant 
mice received abdominal (peritoneal) injections of inactivated influenza vaccine and their 
offspring, too, were protected against a challenge with a lethal dose of influenza virus 
(Mbawuike 1990). Results from both studies indicated that giving influenza vaccine to 
pregnant mice significantly decreased the incidence of influenza infection in their offspring. 
Both animal studies found that breastfeeding was the primary way that passive antibodies 
were transferred to the offspring. Although breastfeeding is thought to be a route of transfer 
of antibody from mother to infants, transfer across the placenta is the primordial route in 
humans (Sweet 1987).  
 
In humans, maternal antibodies cross the placenta via active transport later during gestation, 
presumably around 32 weeks gestation. A study that measured antibody concentration 
(immunoglobulin G) in mothers and their infants found higher antibody concentrations in 
infants than in mothers, suggesting there is active transport of antibodies across the placenta 
(Kohler 1966). Another study measured these antibody levels in 106 premature infants in 
the first week of life and found a logarithmic relationship between the level of 
immunoglobulin G and gestational age, and suggested that infants born at 32 weeks or 
  
10 
earlier may have insufficient protection to fight off some infections (Hobbs 1967). No study 
has examined total influenza-specific antibodies from mother to the offspring. 
 
Influenza antibodies can also be found in cord blood, indicating presence of such antibodies 
at birth, and antibody levels can be studied to determine whether this presence represents 
protection from infection. One study of inactivated influenza vaccine in 56 women in the 
second and third trimester of gestation found influenza antibodies in 58% of maternal sera 
and 42% of infant cord sera, and concluded that a sufficient dose of influenza vaccine given 
during pregnancy could form the basis for protection of the infant. The study also suggested 
that the timing of delivery relative to the influenza season might be an important 
determinant of antibody levels in mothers and their infants (specifically, that delivery 
during influenza season may be correlated with higher levels of influenza antibodies in the 
infant), that multiple doses of influenza vaccine might be needed in pregnancy to provide 
sufficient protection to the infant, and that there was no statistically significant difference 
between vaccinating the mother in the second trimester versus vaccinating her in the third 
trimester (Sumaya 1979). 
 
Studies have shown that mothers who receive inactivated influenza vaccine during 
pregnancy deliver infants who have influenza antibodies that delay the onset and decrease 
the severity of influenza infection, with the degree of protection related to the infant’s 
influenza antibody level at birth. Women who were naturally infected by influenza also had 
infants with similar or higher levels of antibodies (Sumaya 1979; Puck 1980; Reuman 1987; 
Englund 1993). 
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One study showed that giving influenza vaccine to women during pregnancy resulted in 
higher influenza-specific antibody concentrations in infants at birth than in their mothers at 
the same point in time, suggesting active transport from mother to infant. That study gave 
influenza vaccine to 56 pregnant women in the second or third trimester and monitored 
antibody concentrations in 40 mother-infant pairs after birth, and found measurable 
antibody titers in several of the infants, even several months after birth. They suggested that 
vaccination of pregnant women against influenza could help to protect infants via passive 
transfer of maternal antibodies against influenza (Sumaya 1979). Another study measured 
transplacental antibodies (immunoglobulin G) to influenza A in stored cord blood of 26 
infants who had been brought to primary care facilities and had culture-positive influenza 
infection, and found a positive correlation between age at the time of first infection with 
influenza and the level of antibody found in cord serum (in other words, infants who had a 
higher level of influenza antibody in their cord blood at birth had a later influenza infection 
than infants with lower levels of antibody at birth). This suggested that these antibodies are 
protective, that vaccinating pregnant women could prevent symptomatic influenza infection 
in their infants, that breastfeeding could provide an additional level of protection, and that 
the antibody level wanes over time. Infection in the presence of low levels of antibody may 
result in attenuated illness (Puck 1980). A third study of influenza antibodies followed 
women and their offspring in the United States during an influenza A epidemic in 1979 and 
showed that the infants’ concentrations of influenza antibodies at birth correlated with their 
mothers’ antibody concentrations. Infants with higher concentrations of influenza 
antibodies had a delay in the onset and a decrease in the severity of influenza infection 
(Reuman 1987). 
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The active transport of antibodies from mother to infant across the placenta occurs in 
significant quantities and primarily after 33 weeks gestation, and infants born at an earlier 
gestation may be less protected by this immune protection. The presence of maternally-
derived antibodies in infancy does not inhibit development of natural immunity later in life 
from immunization or natural infection. 
 
There are many reasons to consider maternal vaccination as an effective strategy for the 
protection of infants in the first six months of life, including the immature immune systems 
in infants of this age and their vulnerability to common bacterial and viral infections, the 
adequacy of maternal vaccination, and the cost-effectiveness of giving one dose to the 
mother instead of several doses to the infant (Englund 1993, Munoz 2000). Immunizing 
women against influenza during pregnancy is a promising strategy for reducing the burden 
of influenza-related illness in their infants. Breastfed infants may be further protected by 
antibodies (immunoglobulin A) in breast milk (Munoz 2000). Indeed, vaccination of 
pregnant women to protect infants against childhood infection is already in widespread 
practice for bacterial infections such as tetanus and Haemophilus influenzae Type b, and for 
viral diseases such as polio (Munoz 2000). Several vaccines are used in mothers to decrease 
the incidence of diseases including pertussis and tetanus in their infants (GPVI 1996). 
 
Inactivated influenza vaccination given to pregnant women has been shown to be safe and 
immunogenic in women and their infants (Naleway 2006). However, in spite of data on 
safety and the potential benefit to both mother and child, vaccination practices during 
pregnancy are poor and vary widely for different healthcare providers and regions: in the 
U.S. in 2006, 14% of women got influenza vaccine during pregnancy (CDC 2006). Most 
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obstetricians recommend influenza vaccination for pregnant women to protect those women 
against severe infection, yet in 2003 only one third of those recommending influenza 
vaccination during pregnancy offered this vaccine to their patients (CDC 2005). Studies 
have examined the effectiveness of flu vaccination in pregnancy on preventing or 
modifying influenza-related morbidity in infants, however their results have been 
inconsistent. 
 
Two recent studies compared hospitalizations due to influenza in infants and rates of 
influenza-like illness (ILI) or medically attended acute respiratory infection (MAARI) in 
infants whose mothers had received influenza vaccination during pregnancy with those 
whose mothers had not been vaccinated. Neither study found a protective effect associated 
with vaccination during pregnancy; however, both studies included non-influenza infections 
along with influenza infections. One study of hospital admissions with principal diagnoses 
of influenza or pneumonia and ILI in outpatient visits during five influenza seasons from 
1997 to 2002 found that women who received influenza vaccine during pregnancy had the 
same risk for ILI visits as unvaccinated women, and their infants had the same risks for 
influenza or pneumonia compared with other infants whose mothers had not received the 
vaccine (Black 2004). Another study that followed over 41,000 infants for MAARI (another 
measure that combines influenza with other diseases such as pneumonia) in outpatient, 
emergency department, or inpatient settings, found that maternal influenza vaccination did 
not delay the onset of the first respiratory illness (France 2006). 
 
Recently, Zaman et al. conducted a trial of inactivated influenza vaccine given to pregnant 
women in Bangladesh found a 63% reduction in laboratory-confirmed influenza illness in 
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their infants up to six months old compared with administration of pneumococcal vaccine 
(Zaman 2008). This study was conducted outside the US in a region where influenza 
infection circulates year-round, unlike the seasonal pattern of influenza seen in the US in 
recent decades. Mothers were recruited in the third trimester of pregnancy. This study was 
unable to assess effectiveness on hospitalization or severe illness. 
 
Relevance 
 
Influenza infection has significant impacts on society including morbidity and mortality of 
infected individuals, impacts on their families, and healthcare utilization and costs, in the 
U.S. and worldwide. In children, influenza infection takes on added significance because 
there is no vaccine available to protect infants aged <6 months, in contrast to the rest of the 
population which can be protected using the vaccine, and these infants are hospitalized for 
influenza infection at rates similar to the elderly. Even mild cases of influenza may lead to 
lost productivity in society when parents miss work to care for their sick children. Children 
are also one of the major routes of spread of influenza in the population. The possibility of a 
novel approach to protect infants aged <6 months is of significant importance to the medical 
and public health communities. Therefore, proven effectiveness of influenza vaccine given 
to pregnant women will have important public health implications worldwide. If 
immunizing mothers is found to be effective in providing protection to their infants, this 
approach has the potential to improve protection of susceptible infants for whom the 
vaccine is not an option until later in life, and it could also further improve on the cost-
effectiveness of vaccinating pregnant women (Roberts 2006) by protecting two people, 
mother and infant, with just one immunization. Results may also increase awareness of the 
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importance of influenza vaccination during pregnancy (by protecting women who are 
already at high risk for complications from influenza in pregnancy) and it will help 
overcome barriers to vaccination, potentially impacting motivations, perceptions, and 
attitudes of pregnant women and of their medical providers towards vaccination during 
pregnancy. 
 
Statistical power 
 
National surveys in recent years have found that only 13% of pregnant women receive 
influenza vaccine (NHIS 2003), with vaccination rates of pregnant women in Connecticut 
slightly higher, at around 30% (BRFSS 2005). 
 
Hospital data from our institution showed that approximately 30 infants (aged <12 months) 
are admitted with a diagnosis of influenza each year. For this study, we initially anticipated 
enrolling 25 cases and 50 matched controls per season (early in the fall through the winter), 
a total of 75 subjects per influenza season. We also planned to enroll infants prospectively 
over two influenza seasons. 
 
The statistical power to assess the vaccine’s effectiveness depends on the number of 
discordant groups (cases and their matched controls), which in turn depends on the rate of 
influenza immunization among the mothers of the infants. Assuming that 30% of mothers 
are immunized (using the Connecticut data above), enrolling 69 cases would provide 90% 
statistical power to detect an effectiveness of the vaccine of 65%. Our plan was to enroll 
patients who had been hospitalized during the several years prior to the initiation of our 
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study to be able to compare across influenza seasons, and then also to continue enrolling 
cases in the hospital setting for two years to be able to collect nasal wash samples. 
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HYPOTHESIS 
Giving influenza vaccine to women during pregnancy reduces hospitalization of their 
infants due to influenza compared to women who did not receive the influenza vaccine 
during pregnancy. 
 
AIMS 
To assess whether giving influenza vaccine to pregnant women protects their infants against 
influenza infection, leading to a lower relative risk of hospitalization before age 12 months. 
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METHODS 
 
We conducted a matched case-control study of infants at Yale-New Haven Children’s 
Hospital, an academic urban hospital in the northeastern United States. 
 
Eligibility requirements 
 
All subjects were infants aged <12 months, hospitalized at Yale-New Haven Children’s 
Hospital due to laboratory-confirmed influenza between 2000 and 2009, prior to the arrival 
of the 2009 pandemic influenza A H1N1 in this region. Infants up to age 12 months were be 
included because, even though they are potential candidates for influenza vaccine at age 6 
months, they may not have received the vaccine and the protective effect of mother’s 
antibodies against influenza may still be found. 
 
We excluded infants who were adopted at birth, hospitalized for reasons unrelated to their 
respiratory infection (as determined by review of medical records), if their influenza 
infection was acquired in the hospital (nosocomial infection), if their mothers had a 
contraindication to inactivated influenza vaccine (e.g., egg allergy, prior adverse reaction) 
or were unable to consent to participate (e.g., deceased, unknown whereabouts), or if 
neither parent could complete the interview in English or Spanish. Infants who received 
influenza vaccine at least two weeks prior to hospitalization were excluded, as it would be 
impossible to distinguish the effect of vaccination of the mother from the effect of 
vaccination of the infant. 
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Testing for influenza 
 
Infants hospitalized at this facility with symptoms suggesting a possible infection with a 
respiratory virus (including influenza, parainfluenza, and adenovirus) are routinely tested 
using a direct fluorescent antibody (DFA) test kit (Light Diagnostics™, Millipore; 
Temecula, CA) of a nasal swab sample. This test has been shown to be 96.2% sensitive and 
99.0% specific for influenza compared with the polymerase chain reaction technique in our 
hospital’s laboratory (Landry 2008). This testing is done for hospital epidemiology (e.g., to 
help determine the arrival of influenza in this region and to determine the extent of these 
infections in the hospitalized population from week to week) and for patient cohorting (i.e., 
patients with the same respiratory infection may sometimes be placed in a double room 
instead of designating two rooms for appropriate contact precautions). The test result is also 
available to the clinical team and may be used to guide clinical decision-making. 
 
Identification of potential cases 
 
Cases were infants hospitalized due to influenza with documentation of either a nasal swab 
or aspirate that was positive for influenza by DFA as described above. Samples deemed 
inadequate by the clinical virology laboratory were not included. Data collection started in 
June 2007. Subjects hospitalized between 2000 and May 2007 were identified historically 
from the clinical virology laboratory list of all tests for influenza and enrolled by telephone. 
During the 2007–2008 and 2008–2009 influenza seasons, research staff identified cases 
prospectively by reviewing both clinical virology laboratory list of all tests for influenza 
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and the daily list of new hospital admissions to enroll patients in the hospital setting and to 
collect a nasal swab sample for further testing. 
 
Selection of controls 
 
For each case, we identified and enrolled two matched controls, who were hospitalized for 
reasons other than influenza and who were infants found to be negative for influenza by 
DFA. Controls were identified from the same list of all hospitalized patients who had a 
DFA test for respiratory viruses and were negative for influenza, matched to cases by date 
of birth and date of hospitalization. A patient with a nasal swab sample that tested positive 
for another respiratory virus could still be enrolled as a control subject if they were found to 
be negative for influenza. Matching started with the subjects born within 2 weeks of the 
case (two weeks before or after the case’s date of birth) and who were admitted to the 
hospital within 2 weeks of the case (two weeks before or after the case’s date of hospital 
admission) and then, if necessary, proceeded to those born within 4 weeks and admitted to 
the hospital within 2 weeks from the case, then those born within 2 weeks and admitted to 
the hospital within 4 weeks from the case, and finally those born within 4 weeks and 
admitted to the hospital within 4 weeks from the case, until two controls were identified. 
We used a table of random numbers to determine the order in which to contact potential 
eligible subjects within each case-control group. We used risk-set sampling in our selection 
of cases and controls: a person could be counted as a control subject multiple times if they 
had more than one admission during which they met control criteria, but once a person was 
a case (i.e., was hospitalized for influenza) they were no longer eligible to be a control 
afterward (Niccolai 2007). 
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Collection of data and ascertainment of vaccinations 
 
We conducted interviews with the parents of all study subjects to ask questions pertaining 
to demographics, possible confounders such as breastfeeding or susceptible individuals in 
the household, and comorbidities of the infant and the mother, and to identify all possible 
sources of vaccination of the mother during pregnancy or previously. Interviews were done 
in person when a case or control was enrolled prior to hospital discharge, or otherwise by 
phone call. All interviews were conducted by study personnel in either English or Spanish. 
 
Information about vaccinations and comorbidities of the infants was obtained by reviewing 
medical records from their medical care providers in addition to interview data. We 
reviewed the mothers’ medical records from their primary medical providers, obstetricians, 
pharmacies, and anywhere the mother stated she would have received influenza vaccine. 
We used this information to ascertain whether a mother had received influenza vaccine 
during pregnancy, whether she had received the vaccine at any time prior to that pregnancy, 
and whether she had received the vaccine during the same influenza season as the infant’s 
hospital admission. A mother was considered vaccinated during pregnancy if written 
documentation in any record was found indicating receipt of influenza vaccine at least 14 
days prior to delivery of the infant. 
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Clinical severity of influenza for the cases 
 
We collected clinical data from the infants’ (case subjects’) hospital medical records such as 
vital signs suggesting a severe infection (including highest temperature and respiratory rates 
and lowest oxygen saturation levels), physical signs of increased work of breathing (such as 
retractions or nasal flaring), results of available chest radiographs, and need for mechanical 
ventilation and/or admission to the intensive care unit (ICU). We classified the severity of 
these symptoms on a scale of 0–16 points, based on our modification of a previously-
validated scale of severity of respiratory symptoms in infants with respiratory infections 
(Table 1) (Papadopoulos 2002). 
 
Respiratory Specimens 
 
Respiratory samples were collected from case subjects still in the hospital at the time of 
enrollment, using the nasal wash technique. RNA was extracted from the clinical specimens 
using RNeasy Mini Kit per manufacturer instructions (Qiagen, Valencia, CA). Reverse 
transcription and the polymerase chain reaction were performed using primers and 
parameters described by the “WHO/CDC Protocol of realtime PCR for influenza A 
(H1N1)” (CDC 2009) and the AccessQuick RT-PCR System (Promega, Madison, WI). 
 
Statistical Analysis 
 
We calculated a matched odds ratio for vaccination of mothers of cases compared with 
matched controls. The vaccine’s effectiveness was calculated as 1 minus the matched odds 
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ratio multiplied by 100. Conditional logistic regression was used to adjust for potential 
confounders including race, ethnicity, sex, age, daycare attendance, prematurity, 
vaccination of household contacts, breastfeeding, and relevant chronic illness (such as 
asthma or reactive airways disease, chronic lung disease, conditions requiring medical 
equipment to facilitate breathing, cardiac defects, blood disorders, seizures, metabolic or 
endocrine disorders, severe gastrointestinal disease, kidney disease, or spinal cord injury). 
 
A stratified analysis was also conducted to assess for effect modification by age of the 
subject (aged ≥6 months vs. aged <6 months) based on the CDC’s recommendation to begin 
influenza vaccination at age 6 months and literature suggesting that maternal antibodies 
wane at 6–9 months. Whether the subject was identified at the time of hospitalization or 
historically via billing data was also evaluated as a possible confounder or effect modifier. 
 
We also assessed the significance of the clinical severity of influenza infection of the cases 
using a Student’s t-test or Wilcoxon rank-sum test as appropriate. Analyses were conducted 
using SAS® version 9.1.3 for Microsoft (SAS Institute; Cary, NC). 
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RESULTS 
 
Enrollment of subjects 
 
We identified a total of 220 eligible case subjects (infants aged <12 months hospitalized due 
to influenza) between October 2000 and April 2009. Of the 220 eligible case subjects, 36 
(16%) could not be contacted by researchers (for example, because the contact telephone 
numbers and addresses were no longer valid). Of the remaining 184 potential case subjects 
contacted, parents of 27 (15%) refused to participate (for example, because the parents were 
not interested in participating in medical research or they did not feel comfortable releasing 
medical records for research purposes), and 157 (85%) were enrolled. Enrollment started in 
July 2007. Data presented are from October 2000 and April 2009; data collection is on-
going. Of the 157 enrolled case subjects, 33 (21%) were hospitalized between January 2008 
and April 2009 and identified prospectively via active surveillance of laboratory data and 
hospital units and 124 (79%) were hospitalized between October 2000 and May 2007 and 
identified historically via laboratory data and hospital records; of these, 130 (83%) were 
infected with influenza A virus and 27 (17%) with influenza B. For these 157 enrolled 
cases, 430 potential matched controls were identified. Of these 430 potential controls, 114 
(26.5%) could not be contacted. Of the 316 potential controls that we were able to reach, 45 
(14.2%) refused to participate, and 271 (85.8%) were enrolled as controls. 
 
Results presented are for the 113 cases and 192 matched controls (cases with at least one 
matched control) in groups with complete data for the case and matched control. 
Demographic characteristics of subjects identified prospectively and historically only 
  
25 
differed statistically significantly on report of sick household members during the month 
before hospitalization (59.8% vs. 23.3%, p < 0.001), and length of hospital stay (5.0 ± 13.2 
vs. 2.9 ± 3.7 days, p = 0.030).  
 
Subject information and demographics 
 
Characteristics of infants hospitalized with influenza and their matched controls are 
presented in Table 2. Cases and matched controls were comparable on most demographic 
characteristics and risk factors, as described below and presented in Table 2. 
 
The majority of infants enrolled in the study (80.5% of cases and 81.2% of controls) were 
aged <6 months, with slightly more infants aged 0–<3 months (35.4% of cases and 35.9% 
of controls) than infants aged 3–<6 months (45.1% of cases and 45.3% of controls) (Table 
2). There were roughly equal numbers of male and female infants enrolled as case subjects 
(50.4% male and 49.6% female), with slightly more male controls than female controls 
(52.6% male and 47.4% female). The majority of cases and controls were white (around 
two-thirds of each group), and approximately one-fifth of cases were black and 
approximately one-tenth of controls were black, with the remainder in the “other” category. 
 
Cases came from households with a larger number of household members than controls (4.9 
± 2.0 vs. 4.4 ± 1.3, p = 0.015), and they were significantly less likely to live with household 
members that had received influenza vaccine (32.7% cases vs. 50.0% controls for any 
household members vaccinated, and 10.6% cases vs. 15.1% controls for all reported 
household members vaccinated with influenza vaccine; p = 0.001). In subjects aged <6 
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months, the mothers of 2 (2.2%) of 91 cases and 31 (19.9%) of 156 controls had received 
influenza vaccine during pregnancy. In aged ≥6 months, the mothers of 1 (4.6%) of 22 
cases and 2 (5.6%) of 36 controls had received influenza vaccine during pregnancy (p = 
0.809). 
 
There were no significant demographic differences between mothers who received 
influenza vaccine and those who did not receive influenza vaccine (Table 3). In vaccinated 
mothers, cases and controls did not differ significantly in the trimester of pregnancy during 
which vaccination occurred, with 2 (66.7%) case subjects’ mothers and 26 (78.8%) of the 
control subjects’ mothers having received vaccines in the third trimester of pregnancy. 
 
Clinical severity of cases 
 
The median clinical severity scores of the case subjects enrolled was 4 (moderate severity) 
on a scale of 0–16 (Figure 1). Case subjects aged ≥6 months at the time of hospitalization 
had a significantly higher mean severity score than those aged <6 months (6.3 ± 3.1 vs. 4.1 
± 2.7, p = 0.001), and those with chronic medical conditions had higher severity scores than 
those without underlying medical conditions (5.3 ± 2.5 vs. 3.5 ± 2.2, p = 0.003). Differences 
in clinical severity scores of the cases by mother’s vaccination status during pregnancy were 
not statistically significant. 
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Respiratory specimens 
 
The nasal samples obtained from the cases identifies prospectively (2007–2009) were all 
confirmed to be negative for 2009 pandemic influenza A H1N1. This was evaluated by 
comparing the respiratory specimens to known primers for the pandemic influenza strain. 
 
Effectiveness of vaccination 
 
The adjusted effectiveness of the vaccine of 91.5% (95% CI: 61.7%–98.1%, p = 0.001) for 
infants aged <6 months, using a final adjusted model that retained immunization of 
household contacts (persons other than the subject’s mother residing in the household at the 
time of admission) (adjusted odds ratio, 0.420; 95% CI: 0.221–0.798, p = 0.008) and 
prematurity (0.375, 95% CI: 0.153–0.918, p = 0.032). The unadjusted effectiveness of 
influenza vaccine given to mothers during pregnancy in preventing hospitalization due to 
influenza in their infants was 90.7% (95% CI: 59.9%–97.8%, p = 0.001) for this age group. 
The effectiveness of the vaccine for infants aged ≥6 months was -41.4% (95% CI: -
2257.3%–91.5%, p = 0.809). The effectiveness of the vaccine did not differ significantly 
when we compared subjects identified prospectively versus subjects identified historically 
(for historically identified subjects, effectiveness: 88.9%, 95% CI: 13.1%–98.6%, p = 
0.036; for prospectively identified subjects, effectiveness: 92.0%, 95% CI: 37.0%–99.0%, p 
= 0.016; for the Breslow Day test for homogeneity of the odds ratios: p-value = 0.767). 
Also, exclusion of subjects born before 32 weeks of gestational age did not significantly 
affect the estimate. 
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DISCUSSION 
 
Enrollment of subjects 
 
We were able to contact most of the eligible case subjects that we had identified. Reasons 
that eligible cases could not be contacted included hospital records that contained only 
incorrect or outdated telephone numbers, people who had moved since the time of the 
hospitalization and for whom no updated information could be obtained through a search of 
hospital data systems, and people who were believed to still live in the same location but 
could not be reached by telephone or mail inquiries using all available contact information. 
 
A small number of eligible case subjects and eligible control subjects who were contacted 
refused to participate. Although no one single reason predominated this group, some of the 
reasons cited included concern about the privacy of their records (e.g., they did not feel 
comfortable with someone reviewing the child’s medical records and/or reviewing the 
mother’s medical records for reasons unrelated to medical care), disinterest in participating 
in medical research, or that they did not want researchers contacting their physicians at all. 
 
Subject information and demographics 
 
A mother’s chance of being offered influenza vaccine during pregnancy is expected to vary 
depending on the time of year when the pregnancy begins because the influenza vaccine is 
not available year-round, but rather is typically available starting shortly before the arrival 
of influenza virus to a region and continuing until at least partway through that season. 
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However, we expect that this variability did not differ significantly between cases and 
controls because these two groups were closely matched by the infants’ dates of birth. 
 
Clinical severity of cases 
 
The majority of the clinical severity scores were mild to moderate (between 0 and 5 on a 
scale of 0–16), with only a handful of cases in the severe range (a score of 6 or greater). The 
ranges of clinical severity scores presented in Figure 1 (mild, ≤3; moderate, 4–5; severe, ≥6) 
were selected in order to divide the group of cases into roughly equal groups, not based on 
prior assumptions regarding a fixed score that would correspond to a clinically valid 
severity measure or that would suggest an underlying pathophysiology of disease. Eleven 
case subjects (9.7%) were admitted to the ICU. 
 
Effectiveness of vaccination 
 
Our study shows that inactivated influenza vaccine given to pregnant women is highly 
effective (91.5%) in preventing hospitalization due to laboratory-confirmed influenza 
among their infants aged <6 months. These results have great clinical relevance because 
they provide a strategy to confer protection to young infants, a group at high risk for the 
disease and for whom no vaccine is currently available. This strategy also has important 
public health implications as it would protect not only young infants but also their mothers, 
who are also in the high-risk category for severe influenza. Our results on the effectiveness 
of this approach in the United States, where influenza is seasonal, are consistent with 
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findings in a randomized trial of influenza vaccine in Bangladesh, a tropical developing 
country where the pattern and transmission of influenza is perennial (Zaman 2008). 
 
Although there was inadequate statistical power to assess the vaccine’s effectiveness in 
infants aged ≥6 months, an estimate of -41.4% with wide confidence intervals indicates that 
a null effect in this age group is plausible. This difference in protective effect between 
infants aged <6 months (in which a statistically significant protective effect was found) and 
infants aged ≥6 months at hospitalization could be explained by the decline of the 
concentration of passively transferred antibodies, which one would expect to have dropped 
to negligible levels by age 6–9 months and which is supported by earlier work by other 
investigators. The interpretation of this effect is, however, complicated by low numbers. 
 
Study limitations 
 
There were several possible limitations to our study. We lacked statistical power to estimate 
the effectiveness of influenza vaccine for infants aged ≥6 months. It was also not possible to 
assess independently the effects of second versus third trimester vaccination because of 
small numbers, however the study is on-going. Women who received influenza vaccine 
after birth or in the final two weeks of pregnancy, and who breastfeed their infant for any 
period of time, are not expected to transfer influenza antibody across the placenta but they 
could still transfer influenza antibody in breastmilk: this effect could not be studied in our 
population due to the small number of women receiving influenza vaccine at this time and 
the low power to evaluate this question. Furthermore, our study did not have adequate 
power to assess the vaccine’s effectiveness by influenza season, allowing us to assess for 
  
31 
year-to-year variability. Future prospective studies are needed to evaluate longer-term 
effectiveness, in subsequent influenza seasons, of this novel strategy. 
 
We have yet to conduct complete laboratory typing of strains to determine whether 
influenza infections seen in case subjects were due to strains included in the vaccine or the 
degree of mismatch between infecting strains and vaccine strains. We also did not evaluate 
seasonal variability for any relationship between infecting strains and common circulating 
strains, which could induce immunity in the mothers even in the absence of vaccination. 
Further research is needed to evaluate both of these possibilities. 
 
This study includes patients who were hospitalized over nine annual influenza seasons, but 
data collection, including surveys given to parents of subjects, began seven years after the 
earliest dates of hospitalization in these cases and controls. It is possible that recall bias 
could have influenced the ability of mothers to recall information that could not be verified 
by the medical record, such as the length of time they breastfed their infants, the number of 
other people living in the household and their vaccination status and age, and other 
information collected on the survey; we would expect that the reliability of recall for 
seasonal influenza vaccination and other information would decrease over successive years. 
 
This study was conducted during years when three influenza virus strains circulated that 
were similar to strains that had circulated in the global human population for many decades. 
This was prior to the arrival of the 2009 pandemic influenza strain in this region, confirmed 
by laboratory analysis of collected nasal wash samples as described above. The pandemic 
was considered to have ended by January 2010. CDC anticipates that the pandemic strain 
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will circulate along with other strains. It is not known whether the presence of this strain 
will change the seasonal pattern of influenza infections or other aspects of the epidemiology 
of influenza infections in the United States. The results of this study are not anticipated to 
change based on an altered seasonal pattern of influenza or other factors. The possibility 
exists that such shifts could alter the effectiveness of this approach, for example by altering 
the part of the population that is infected or the age groups that are at highest risk. 
 
Earlier studies found lower degrees of protection associated with influenza vaccination in 
the mother compared to our results. The restriction of the case definition to laboratory-
documented influenza infection would be expected to increase the effectiveness of the 
maternal vaccination approach. The possibility also exists that our estimate is higher than 
the effectiveness in the general population because our controls were infants who were 
hospitalized. For example, if mothers of infants in the hospitalized population are less likely 
to have received influenza vaccine during pregnancy compared with mothers of infants in 
the general population, this could lead to an overestimate of the effectiveness in our study. 
Further studies could evaluate this relationship as well as possible connections between a 
subject’s socioeconomic status and the likelihood of the mother receiving influenza vaccine. 
 
Study implications 
 
The CDC and the American College of Obstetrics and Gynecology recommend inactivated 
influenza vaccination for women who will be pregnant during the influenza season (Fiore 
2009) and inactivated influenza vaccination given to pregnant women has been found safe 
and immunogenic (Naleway 2006). Despite data on the safety of inactivated influenza 
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vaccine for pregnant women and the potential benefit to both mother and infant of this 
strategy, rates of vaccination with influenza vaccine in pregnant women are poor and vary 
widely for different healthcare providers and regions (CDC 2006). Most obstetricians are 
aware of the recommendation for pregnant women to receive influenza vaccination as a 
means of protecting women against severe infection. However, in 2003 only one third of 
those that recommended influenza vaccination during pregnancy offered this vaccine to 
their patients (CDC 2005). In our sample, only 17.2% of mothers of control subjects 
received influenza vaccine during pregnancy. It is notable, however, that rates of influenza 
vaccination in pregnancy have improved steadily through recent years; 10% controls in 
2000-2004, 15% controls in 2005-2007, and 35% controls in 2008-2009 were born to 
mothers that had received influenza vaccine during pregnancy, a similar trend to national 
data from these years (Fiore 2009). 
 
The public health implications of our findings are important for several reasons. First, they 
provide further evidence for a novel, effective strategy for the protection of the infant in the 
first six months of life through vaccination of the mother during pregnancy, a novel means 
of protecting infants against hospitalization due to influenza and an approach that is not in 
widespread use nor widely known among expectant parents concerned about the health of 
their infant. Second, many pregnant women currently do not receive influenza vaccine in 
pregnancy, and this may also serve as an incentive for those women (who are also at high 
risk for complications from influenza) to accept influenza vaccine, and for their providers to 
offer it. Hopefully, this evidence could also be used in community and public campaigns to 
improve the overall vaccination rates in this high risk group and the degree of protection of 
their infants. Also, the use of influenza vaccine in pregnant women has previously been 
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found to be cost-effective, and this strategy improves upon that cost-effectiveness (Roberts 
2006). Influenza vaccine given to pregnant women is an effective approach to reducing 
hospitalization due to influenza in their infants under 6 months old. 
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Table 1: Clinical Severity Scale Used to Assess Severity of Influenza 
(Mild, 0–3; Moderate, 4–5; Severe, 6–16) 
Point Value Parameter 
0 1 2 
Heart rate (max # of beats per min)       
 Age 0-7 days <130 130-160 >160 
 Age 1-4 weeks <135 135-170 >170 
 Age 1-6 months <140 140-170 >170 
 Age 6-12 months <130 130-160 >160 
Respiratory rate (max # of breaths per min)    
 Age 0-1 month <50 50-70 >70 
 Age 1-6 months <30 30-50 >50 
 Age 6-12 months <20 20-40 >40 
Oxygen saturation (by pulse oximeter) ≥94% – <94% 
Wheezing No Yes – 
Retractions (intercostal, subcostal, etc.) No – Yes 
Nasal Flaring No Yes – 
Required intubation/mechanical ventilation No – Yes 
Required ICU care No – Yes 
Abnormal chest x-ray No – Yes 
ICU: intensive care unit
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Table 2: Characteristics of Infants Hospitalized with Influenza and Controls 
Characteristic Cases (%) 
(N = 113) 
Controls (%) 
(N = 192) 
P-value 
Age (months)   0.998 
 0–<3 40 (35.4) 69 (35.9)  
 3–<6 51 (45.1) 87 (45.3)  
 6–<9 12 (10.6) 19 (9.9)  
 9–<12 10 (8.9) 17 (8.9)  
 Mean (± standard deviation) 3.2 ± 2.8 3.1 ± 2.9  
 Median 2.0 2.0  
Male gender 57 (50.4) 101 (52.6) 0.715 
Hispanic ethnicity 45 (39.8) 59 (30.7) 0.106 
Race   0.135 
 White 73 (64.6) 129 (67.2)  
 Black 21 (18.6) 21 (10.9)  
 Other 19 (16.8) 42 (21.9)  
Ever breastfed 59 (55.7) 115 (67.3) 0.052 
Attends daycare 11 (9.8) 18 (9.4) 0.898 
Environmental tobacco smoke 
exposure 35 (31.0) 56 (29.2) 0.739 
Premature (gestational age ≤37 
weeks) 13 (11.6) 37 (19.3) 0.082 
 Gestational age <32 weeks 1 (0.9) 10 (3.5)  
 Gestational age 32-36 weeks 12 (10.7) 27 (14.1)  
Chronic medical conditions1 41 (36.3) 74 (38.5) 0.695 
 Respiratory conditions 25 (22.1) 25 (24.5) 0.640 
Type of residence   0.028 
 Single family home 56 (49.6) 110 (57.3)  
 Multi-family home 22 (19.5) 26 (13.5)  
 Apartment 31 (27.4) 56 (29.2)  
 Other setting2 4 (3.5) 0 (0.0)  
Mean number of people at home, 
including subject, ± standard 
deviation; median 
4.9 ± 2.1 
5.0  
4.4 ± 1.3 
4.0 0.015 
Household contacts who had 
received influenza vaccine   0.001 
 None 64 (56.6) 67 (34.9)  
 Some 37 (32.7) 96 (50.0)  
 All 12 (10.6) 29 (15.1)  
1 Includes respiratory conditions (asthma, reactive airways disease, chronic lung disease, and 
conditions requiring medical equipment to facilitate breathing) as well as heart defects, blood 
disorders, seizures, metabolic or endocrine problems, severe stomach problems, kidney disease, 
and spinal cord injuries. 
2 Other settings include dormitories, shelters, and mobile homes. 
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Table 3: Effectiveness of Influenza Vaccine Given to Mothers During Pregnancy  
in Preventing Hospitalization Due to Influenza in their Infants 
 Subjects aged <6 months Cases (%) / Controls (%)  
Subjects aged ≥6 months 
Cases (%) / Controls (%) 
Mother Vaccinated 2 (2.2) / 31 (19.9) 1 (4.6) / 2 (5.6) 
Mother Not vaccinated 89 (97.8) / 125 (80.1) 21 (95.5) / 34 (94.4) 
Unadjusted     
 Vaccine Effectiveness 
[95% CI] 
90.7% [59.9% – 97.8%] 
p = 0.001 
-41.4% [-2257.3% – 91.5%] 
p = 0.809 
Adjusted1     
 Vaccine Effectiveness 
[95% CI] 
91.5% [61.7% – 98.1%] 
p = 0.001 . 
1Adjusted model for subjects aged <6 months retained vaccination of household contacts and 
prematurity.  
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Table 4: Receipt of Influenza Vaccine by Subjects’ Mothers 
 Cases (N = 113) 
Controls 
(N = 192) P-value 
Vaccination status during pregnancy   <0.001 
 Not vaccinated 110 (97.4) 159 (82.8)  
 Vaccinated 3 (2.7) 33 (17.2)  
  During hospitalization season 2 (1.8) 32 (16.7)  
  During prior season 1 (0.9) 1 (0.5)  
For those vaccinated during pregnancy, 
timing of vaccination in pregnancy   0.541 
 First trimester 0 (0.0) 0 (0.0)  
 Second trimester 1 (33.3) 7 (21.2)  
 Third trimester 2 (66.7) 26 (78.8)  
During influenza season when infant was 
hospitalized, mother   <0.001 
 Not vaccinated 109 (96.5) 155 (80.7)  
 Vaccinated 4 (3.5) 37 (19.3)  
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Figure 1: Clinical Severity Score by Age Group
(p = 0.003)
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STUDY PERSONNEL 
 
I worked with Dr. Marietta Vázquez and Dr. Eugene Shapiro for the first 18 months of the 
study.  Dr. Vázquez and Dr. Shapiro provided oversight. I identified case and control 
subjects using data from hospital records, made phone calls to enroll participants, and 
enrolled cases and controls in the hospital during 2007-2008. In August 2008, Daina 
Esposito took over management of this study: she identified case and control subjects, 
enrolled additional participants, reviewed records and conducted much of the data analysis. 
Kristina Gracey, Nancy Holabird, Marcella Mignosa, Heather Yates, Matthew Burke and 
other personnel assisted with enrolling cases and controls, reviewing records, building an 
electronic database for results, and other study tasks. RT-PCR analysis of nasal wash 
samples was done by Madison Hustedt and Dr. Richard Martinello. 
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PATIENT INTERVIEW FORM 
 
INFANT INFORMATION 
 
“First I would like to ask some general questions about [child].” 
 
1. “What is your relationship to [child]?” 
1 Mother/stepmother  
2 Father/stepfather      
3 Grandparent   
4 Other*   *If OTHER, specify:________________________ 
      5 Guardian    
 
2. “Is [child] Hispanic or Latino?” 
1 Yes    
0 No     
9 Unknown    
 
3. “Which one or more of the following is [child] race?” (Check all that apply) 
 1 White       
 2 Black or African American    
 3 Asian       
 4 Native Hawaiian or Other Pacific Islander  
 5 American Indian or Alaska Native   
 6     Other*      *Specify: ______________ 
 7 Don’t know/Not sure     
 9 Declined to answer     
 
4. “Is [child] an adopted child or living in foster care?” 
1 Yes  
0 No   
9 Unknown  
 
5. “What was [child]’s birth weight?” 
____ lbs ____ozs (OR)         _________ grams 
 
6. “Was [child] born early (prematurely)?” 
1 Yes   *If YES: “At how many weeks/days was he/she 
born?” 
0 No       ____ weeks + 
9 Unknown      ____ days 
 
7. Did [child] have to stay in the hospital more than 4 days after birth? 
1 Yes   *If YES, “How many days?”  
0 No       ____ days 
9 Unknown  
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8. “Was [child] ever breastfed?” 
Yes* 1* 
No  0 
Unknown 9 
Still BF 11 
 
*IF YES: “How many months old was [child] when all breastfeeding stopped?”___ ___  
(# complete months – mark ”99” if unknown) 
“For how many weeks was [child] breastfed exclusively?”___ ___   
 
“Next, I am going to ask several questions about a specific period of time. This period 
is the 30 days right before your child was hospitalized, which is from __/__/____ to 
__/__/____.  
I will refer to this as the reference period.” [The reference period begins 30 days prior to 
date of admission (or the child’s date of birth, whichever comes later, and ends on the date 
of admission.] 
 
“I’d like to begin by asking some general questions about your household during the 
reference period that I just mentioned. 
 
9. “I’m going to read a list of different types of residences. Can you please tell me 
which best describes the type of residence in which [child] lived during the 
reference period?” 
Single family house   1 
Duplex or Multi-family house  2 
Apartment/Condominium   3 
Mobile home/Trailer   4 
Dormitory               5 
Shelter     6 
Other     7 
Don’t know/Refuse   9 
 
10. “So, during the reference period of ______, how many people were living or 
staying in this household? Include you, your child, foster children, roomers, 
housemates, people staying here that had no other place to stay, long-term visitors, 
and people living here most of the time while working, even if they had another 
place to live.”                        
____ ____ (# of people - mark “99” if unknown) 
 
11. “Please tell me the ages of all the people who lived in the household, including you 
but not counting [child] and tell me their relationship to [child]. I would like to 
know the ages during the reference period. Please also tell me if each person 
smoked at least once during the reference period. Finally, if you recall that any of 
these people were sick during the reference period, please let me know that 
information, too.” 
 (record responses in table on next page) 
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Note: Please fill out table below for each person living in the house. Circle where appropriate. Do not include 
the case/control child. Cigars and pipes should also be included for smoking data.  
Relationship codes: 1=mother/stepmother, 2=father/stepfather, 3=sibling, 4=grandparent, 5=aunt/uncle, 
6=cousin, 7=friend of family, 8=other. 
   
Note: check the total household members against Question 10; clarify any potential 
discrepancies 
 
12. “So, during the reference period, there were ____ [count from above] people under 
the age of 18 sleeping in the same room as [child]?”   (Fix numbers if there is a 
discrepancy) 
 
13. “Which best describes the highest level of education that the child’s caretaker has 
received?” 
  No high school           1 
Some high school     2    
  High school graduate/GED    3 
Technical school     4  
  Some college      5 
College graduate     6 
Post graduate/professional    7 
Don’t know/refused     8 
 
14. “Which of the following categories best describes your total household income?” 
     Up to $15,000      1 
$15,000 to $30,000     2  
 
Received seasonal 
flu vaccine by end 
of ref period? 
 
Received H1N1 
flu vaccine by end 
of ref period? 
 
Relation 
to [child] 
 
Age 
during 
ref. 
period 
 
Unit of 
age 
Years 
or 
Months 
 
Smoker? 
(yes, no, 
unknown) 
Type: Nasal (live intra-nasal) IM 
(attenuated intra-muscular) 
 
Slept in 
same room 
as child 
during ref. 
period? 
 
Was 
person 
sick 
during ref. 
period? 
 
Notes 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
 
  Yr Mo Yes No 
UK 
Nasal  IM  No  UK Nasal  IM  No  UK Yes No 
UK 
Yes No 
UK 
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  $30,000 to $45,000     3 
$45,000 to $60,000     4  
  More than $60,000     5 
Refused      6   
  Don’t know      7 
 
“Now, I would like to ask you some questions about [child]’s daycare during the 
reference period.  The definition of daycare for this evaluation is any setting outside of 
your home where your child regularly spent 4 or more hours per week with at least 2 
other children of any age under the care of an adult. Include preschool if your child 
attended for more than 4 hours/wk. If child care is provided in your home for others, 
think of your child as attending day care if care is provided for at least 2 unrelated 
children for 4+ hrs/wk with [child].” 
 
15. “During the reference period, did [child] attend any daycare, as we have just 
defined it?” (If child attended >1 daycare, have respondent answer in relation to the 
site where the child spent the most time during the week.) 
Yes  1 
No  0  (Skip to Q. 22) 
Unknown 9  (Skip to Q. 22) 
 
16. “How many hours per week did [child] attend daycare during the reference 
period?” (Add total hours per week for all daycare ctrs.) 
 _______=   Total hours/week (mark “999” if unknown) 
 
17. “For how many months before hospitalization did [child] attend this daycare?” (If 
child attended >1 daycare, instruct respondent to answer question in relation to the site 
where the child spent the most time during week.) 
____ ____ (# months – mark ”99” if unknown, or ”00” if less than 1 month) 
 
18. “What type of daycare did [child] attend during the reference period? I will read 
several options.” (If child attended >1 daycare, instruct respondent to answer in 
relation to the site where the child spent the most time during week) 
Daycare center*  1*   
 Preschool*  2*  
Home daycare  3   
Other   4   
 Don’t know  9 
 *If response is either Daycare center (1) or Preschool (2), then also ask Question 19: 
 
19. “During the reference period, how many children, including [child], were in the 
same classroom or daycare setting as [child]?” (If child attended >1 daycare, instruct 
respondent to answer in relation to the site where the child spent the most time during 
the week)  
  ____ ____  (# of children – mark “99” if unknown) 
 
  
51 
20. During the reference period, how many children, including [child], attended the 
same daycare facility as [child]?” (If child attended >1 daycare, instruct respondent 
to answer in relation to the site where the child spent the most time during week) 
   ____ ____  (# of children – mark “99” if unknown) 
 
21. “Were cigarettes smoked inside any facility or home where [child] attended day 
care?” 
Yes 1  
No  0 
Unknown 9 
 
“Now I would like to ask you a few questions about [child]’s general health. I will read 
a list of health problems. Some terms may be unfamiliar to you because they do not 
apply to your family. I will be happy to repeat or explain any terms. I will ask you to 
indicate if you were ever told by a physician that [child] had any of these conditions. 
Please answer Yes, No, or Don’t know. Answer Yes only if the condition started before 
the end of the reference period.” 
 
CASES: “Answer NO if the condition started as part of your child’s influenza 
infection.” 
CONTROLS: “Answer NO if the condition started as part of your child’s 
hospitalization.” 
 
22. “Sickle cell disease?” (Note: SS or SC disease, not SC trait or being a carrier) 
Yes 1  *If YES, specify________________________ 
No  0 
Unknown 9 
 
23. “Kidney or renal disease?” 
Yes* 1*  *If YES, specify type____________________ 
No  0 
Unknown 9 
*IF YES: “Does the child require dialysis?” 
Yes  1 
No  0 
Unknown 9 
 
24. “Heart problems?” 
Yes* 1*   *If YES, specify type_____________________ 
No  0 
Unknown 9 
 
25. “Any chronic problems with the immune system, including any immune system 
problem your child was born with?” 
Yes 1*   *If YES, specify type_____________________ 
No  0 
Unknown 9 
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26. “Asthma, reactive airways disease, or >1 episode of wheezing?” 
Yes* 1*   *If YES, specify type_____________________ 
No  0 
Unknown 9 
IF YES: “From birth to hospitalization, how many times did [child] go to the 
doctor or emergency room for an attack of asthma, reactive airways disease, or 
wheezing?” __ __     (# of visits – mark “99” if unknown) 
 
27. “Other chronic lung condition/s?” 
Yes* 1*    *If YES, please specify type ____________________ 
No  0 
Unknown 9 
 
28. “A birth defect or chronic condition that makes breathing or swallowing 
difficult?” 
Yes* 1*   *If YES, please specify type____________________ 
No  0 
Unknown 9 
 
29. “A condition that needs medical equipment to make breathing or handling 
secretions easier, such as receiving supplemental oxygen, or for which an operation 
was done, such as a tracheostomy (a ‘trach’)?” 
Yes*   1*   *If YES, please specify type____________________ 
No    0 
Unknown 9 
 
30. “Spinal cord injury?” 
Yes* 1*   *If YES, please specify type____________________ 
No  0 
Unknown 9 
 
31. “A seizure disorder or epilepsy?” 
Yes* 1* 
No  0 
Unknown 9 
 
*IF YES: “Are seizures only with fever?” 
Yes 1 
No* 0*     *If NO, please specify type____________________ 
Unknown 9 
 
32. “Severe developmental delay or mental retardation?” 
Yes 1*   *If YES, please specify type____________________ 
No  0 
Unknown 9 
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33. “Any neurologic or neuromuscular problems?” 
          Yes*   1*   *If YES, please specify type____________________ 
           No    0 
         Unknown    9 
 
34. “Any metabolic or endocrine problems?” 
Yes* 1*   *If YES, please specify type____________________ 
No  0 
Unknown 9 
 
35. “Any serious stomach problems?” 
Yes* 1*   *If YES, please specify type____________________ 
No  0 
Unknown 9 
 
36. “Any other chronic illnesses?” 
Yes* 1*   *If YES, please specify type____________________ 
No  0 
Unknown 9 
 
“Now, I would like to ask you some questions regarding medicines that [child] may 
have taken during the reference period.” 
 
37. “During the reference period, did [child] ever take aspirin for more than a 
month?” 
Yes 1 
No  0 
Unknown 9 
 
38. “During the reference period, did [child] take any steroid medications, such as 
Prelone, prednisilone, prednisone, Decadron, dexamethasone or Orapred, either by 
mouth as pills or liquid or by injection? These medications are sometimes given for 
asthma or other illnesses.” [Note: don’t include inhaled steroids.] 
Yes* 1* *If YES: How many days? ___ ____ 
No  0 
Unknown 9 
 
39. “During the reference period, did [child] use any medications for wheezing, 
reactive airways disease, or asthma?” 
Yes 1*   *If YES, please specify type____________________ 
No  0  (Skip to Q. 42) 
Unknown 9 
 
40. “During the reference period, how many different breathing medications did 
[child] use on an average day?” 
   ____ # different medications 
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41. “How many doses per day on average did [child] use these medications? For 
example, if [child] took two medicines twice a day, that would be 4 doses. Please 
include inhaled doses, pills, or liquids taken through a nebulizer.” 
Less than 1 0   1 or 2 times  1  
3 or more times 2   Don’t know  9 
 
42.  “Did [child’s name] get at least one flu shot?” 
 Yes  1* *If Yes, number of doses: 1 2  Unknown 
No  0   
Unknown 9 
 Child <6 mo 11 
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INFORMATION ABOUT THE MOTHER 
 
“Now I want to ask you information about your pregnancy and your health.” 
 
43. “Did you routinely visit a doctor/healthcare provider while pregnant?” (prenatal 
care) 
Yes* 1* 
No  0 
Unknown 9 
 
*If YES: “Approximately how many weeks pregnant were you when you went to 
visit a doctor/healthcare provider for the first time?” 
   _____ weeks 
 
44. “Did you visit >1 one clinic/office when pregnant, including any other primary 
care physicians?” [If you already specifically asked about this during earlier data collection, 
skip.]  
 
Yes* 1  * If YES, record other doctors on the cover page. 
No  0 
 
45. “Approx. how many times did you visit the doctor while pregnant?” 
   Approximate # visits 
    “Normal” number (1/mo early, 2- 3 visits/month in 3rd trimester) 
 
46. “Were you ever hospitalized during this pregnancy?” 
Yes* 1*   *If YES, explain:______________________________ 
No  0   ______________________________________ 
      ______________________________________ 
 
47. “Do you have asthma or chronic obstructive pulmonary disease (COPD)?” 
Yes 1*   *If YES, explain:______________________________ 
No  0   ______________________________________ 
Unknown 9   ______________________________________ 
 
48. “Do you have any long-standing/chronic medical problems?” 
Yes* 1*   *If YES, explain:______________________________ 
No  0   ______________________________________ 
Unknown 9   ______________________________________ 
 
49. “Do you smoke?”   Smoking 
details:_________________________ 
 Yes* 1               (past/present)   _________________________ 
 N o  0              
_________________________ 
 (Compare response against data from question 11. This should reflect status at 
hospitalization.)       
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50. “Did you smoke during the pregnancy?” 
 Yes 1 
 No  0 
 
51. “With this child, were you pregnant with more than one child?” 
Yes* 1*      If YES, specify: ___________________ 
 No 0    (i.e., twins, triplets) 
 
52. “How many children do you have now (only count live children)?” 
   ____ ____ (# of children – mark “99” if unknown) 
 
53. “Did your doctor/healthcare provider recommend you get flu vaccine when you 
were pregnant?” 
Yes  1 
No              0 
Unknown   9 
 
54. “Did you receive influenza vaccine (the flu shot) during this pregnancy?” (check 
with response to #11) 
Yes*  1* If yes, give details:     ________________________________ 
No              0     (year, location) ________________________________ 
Unknown   9    ________________________________ 
 
55. “Other than when you were pregnant, did you EVER receive flu vaccine (before 
your child was hospitalized)?” (check with response to #11) 
Yes*     1*  If yes, give details:    ________________________________ 
No                 0    (year, location) ________________________________ 
Unknown      9          ________________________________ 
 
56. Have you ever received ANY vaccines (other than the flu shot) outside of your 
primary care physician or obstetrician, for example at a pharmacy, at work or at a 
public health department?” 
 Yes* 1* If yes, give details:  ________________________________ 
No  0      (year, location) ________________________________ 
Unknown 9    ________________________________ 
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HOSPITAL RECORD DATA FORM 
 
Study ID____________________ 
                                                                                   Checked by: ____ Date checked: _____________ 
Admission date ____/___/_____     
  MM/DD/YYYY   Sample (check all that apply): 
DOB   ____/___/_____   __ Research team; date collected  ___/___/_____ 
Age at hospitalization (wks) __________ __ Leftover sample; date sent   ___/___/_____ 
 
Reviewer’s initials ____   Date of record review __________ 
                  
Hospital Medical Record Extraction Form 
 
1. Vitals:   Tmax ___C  Axillary   Rectal  HRmax ____   RRmax ___   O2Satmin ___  on RA      
 
2. Labs 
WBC ________      Diff:   ____G   ____L   ____M   ____E  ____Bands 
DFA _________________ 
H1N1 PCR___________________ 
hMPV PCR__________________________ 
Sputum Culture ______________________ 
Blood Culture________________________ 
ABG _______________ 
CSF results 
 Culture/gm stain________________________  
 Cell counts: ____rbc ____nuc cells (___G  ____L  ___M) 
 Virology__________________________________________ 
        Urine culture________________________ 
        Other ____________________ 
 
3. Wheezing on exam        Yes     No    Not recorded 
Nasal flaring on exam    Yes     No    Not recorded 
Retractions on exam      Yes     No    Not recorded  
Details_______________________________________ 
 
4. Imaging 
CXR ___________________________________________________ 
Chest CT _______________________________________________ 
 
5. Treatments given for this sickness at PCC, ED and/or hospital 
______________________________________________________________ 
______________________________________________________________ 
 
 Require 02: Yes     No    If YES, details________________________ 
6. Diagnoses:_______________________________________________ 
 
7. Reasons for admission:_______________________________________________ 
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8. Hospital admission   Yes   No 
8a. If admitted, type: Floor ICU 
 
9. Require ICU care   Yes   No 
 
10. Length hospital stay       _____ days 
 
11. Intubation   Yes   No                                   
 
12. Death     Yes   No 
 
Pre-existing medical conditions/co-morbidities: 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
 
 
Also note the presence/absence of these symptoms: Recording method: 
 
Sneeze Yes No Unknown ___ Observed by 
Cough Yes No Unknown  study personnel 
Rash Yes No Unknown ___ Information is 
Nasal discharge Yes No Unknown  from records 
 
Appearance: Well Ill Toxic 
 
Other pertinent clinical information: (be sure to note recent antibiotic use if any) 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
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RESPIRATORY CLINICAL SEVERITY SCALE 
 
 
Date: ___/___/___ Time: ___:___ [am/pm]  Scored by: _____ (initials) 
 
 0 pts 1 pt 2 pts 
1. Heart Rate (max):  ______ beats/min    
     Age 0-7 days <130 130 – 160 >160 
     Age 1-4 weeks <135 135 – 170 >170 
     Age 1-6 months <140 140 – 170 >170 
     Age 6-12 months <130 130 – 160 >160 
    
2. Respiratory rate (max):  ______ breaths/min    
     Age 0-1 month <50 50 – 70 >70 
     Age 1-6 months <30 30 – 50 >50 
     Age 6-12 months <20 20 – 40 >40 
    
3. Oxygen saturation:  ______% ≥94% –– <94% 
    
4. Wheezing present? No Yes –– 
    
5: Retractions present? No –– Yes 
    
6. Nasal flaring present? No Yes –– 
    
7.  Require intubation? No –– Yes 
    
8. Require ICU care? No –– Yes 
    
9.  Abnormal chest x-ray? No –– Yes 
    
TOTAL SCORE (0-16): ___________    
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OUTPATIENT MEDICAL GROUP INFORMATION 
Clinic or group: ________________________________________________ 
Physician(s):  ________________________________________________ 
Address:  ____________________   ___________   ____   ________ 
Phone number:  (____) ____ - ______ (voice)  /  (____) ____ - ______ (fax) 
Type:  Pediatrics  Family  Hospital  
  Ob/gyn  PMD  L&D  Other: ________________ 
Date of this interview:  ______/______/______ Reviewer initials: __ __ __ 
Interviewee_____________________________ 
 
1. Have you ever given the flu vaccine in this office or in any other office of this 
medical group? 
 
 Yes  If YES, when did you start/stop offering the vaccine? _______________ 
 No 
 
2. If YES for at least one season: 
 
Do physicians in this office recommend flu vaccine to their patients?  
 Yes, for children as per CDC recommendations 
 Yes, for pregnant women as per CDC recommendations 
 Other: ________________________ 
 No 
 
If the flu vaccine is offered to pregnant women, when is the vaccine administered? 
 1st trimester 
 2nd trimester 
 3rd trimester 
 
How was the vaccination information recorded?  
 In the patient’s medical records 
 In the medical group’s billing records 
 Other: _______________________ 
 
How can the vaccination information be obtained?____________________ 
 
3. If NO for at least one season: 
 
If a patient had asked for flu vaccine in these seasons, what would have happened? 
 The patient would have been directed elsewhere: ___________________ 
 We would not have provided any further information or assistance 
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OUTPATIENT MEDICAL RECORD REVIEW – INFANT 
Subject’s Name:          ________________________________________________ 
Notes about practice__________________________________________  Faxed info:  
Type:  Pediatrics  Family  Hospital  Other: ________________ 
Infant DOB: ______/______/_______ Last time seen:  ______/______/______ 
Admit Date of case/control: ______/______/______  Flu season: ____-____ 
Date of this record review:  ______/______/______  Reviewer initials: _____
  
Insurance Provider: No___   Yes____   If yes: _____      ______      _______________ 
        Public      Private       Company 
 
VACCINATION RECORD 
DTaP 
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
 Dose 3: ____/____/____ 
 Dose 4: ____/____/____ 
 Dose 5: ____/____/____ 
 
Hepatitis B 
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
 Dose 3: ____/____/____ 
 Dose 4: ____/____/____ 
 
Polio (IPV) 
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
 Dose 3: ____/____/____ 
 Dose 4: ____/____/____ 
 Dose 5: ____/____/____ 
 
Haemophilus influenzae B (Hib) 
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
 Dose 3: ____/____/____ 
 Dose 4: ____/____/____ 
 Dose 5: ____/____/____ 
 Dose 6: ____/____/____ 
 
Hepatitis A Vaccine 
 Dose 1: ____/____/____ 
Dose 2: ____/____/____ 
Prevnar                                                   
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
 Dose 3: ____/____/____ 
 Dose 4: ____/____/____ 
 
Influenza vaccine 
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
 Dose 3: ____/____/____ 
 Dose 4: ____/____/____ 
 Dose 5: ____/____/____ 
 Dose 6: ____/____/____ 
 Dose 7: ____/____/____ 
 
MMR  
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
 
Varicella Vaccine 
 Dose 1: ____/____/____ 
Dose 2: ____/____/____ 
 
Rotateq  
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
 Dose 3: ____/____/____ 
 
RotaRix 
 Dose 1: ____/____/____ 
 Dose 2: ____/____/____ 
Common Combination Vaccines 
(please circle and add dates) 
 
Pediarix (DTaP, Hep B, IPV) 
 
______________________________ 
 
Comvax (HepB and Hib) 
 
______________________________ 
 
TriHIBit (DTaP and Hib) 
 
______________________________ 
 
ProQuad (MMR + Varicella-
MMRV) 
 
______________________________ 
 
Pentacel (DTap, Hib, IPV) 
 
_______________________________ 
 
Other vaccine notes: 
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(continued) 
 
Date of birth:  ____ / ____ / _____ Weeks gestation: ______ 
Birthweight:   ____ lbs ____ oz  OR ______ grams 
Place of Birth:_______________________________________________________ 
Child’s other physicians, if listed_________________________________________ 
 
Please list all medications and pre-existing medical conditions. 
 
All pre-existing medical conditions: 
 
Specifics to look for: 
 Sickle cell disease 
 Kidney/renal disease 
 Heart problems 
 Chronic immune 
problems 
 Asthma, reactive 
airways disease, or 
wheezing 
 Birth defects  
 Conditions requiring 
med equip for 
breathing 
 Spinal cord injury 
 Other chronic 
illnesses 
 Seizures or epilepsy 
 Developmental delay 
or mental retardation 
  
All chronic or recent medications before acute illness: (route + dose) 
 
Specifics to look for: 
 
Steroid medications 
 Prelone, Prednisolone 
Prednisone, Decadron, 
Dexamethasone, 
Orapred 
 
Medications 
 Albuterol 
 Aspirin (long term) 
Be sure to include the 
type, route and dose for 
all medications listed 
here. 
Acute illness – brief history 
# visits to clinic or practice for acute illness ___ 
 
 
Other pertinent information noted in medical record: 
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OUTPATIENT MEDICAL RECORD REVIEW – MOTHER 
Reviewer initials: __ __                                     Date of record review:  
______/______/______  
Any other physicians listed 
______________________________________________________ 
Where child was 
delivered_______________________________________________________ 
Date of birth:  ____ / ____ / _____     Date of admission:  ____ / ____ / _____ 
Birth weight:   ______ (circle: lb/oz  grams)    Weeks gestation: ______ 
Insurance Provider: No___   Yes____  If yes:    ____         _____        ________________ 
                                      (0)           (1)                  Public       Private       Name of Company 
Mother received flu vaccine at this practice? 
 
Yes, dose 1 date: ____ / ____ / ____Type:   TIV inactivated  LAIV, live, attenuated 
Yes, dose 2 date:____ / ____ / ____Type:  TIV, inactivated  LAIV, live, attenuated 
Yes, dose 3 date:____ / ____ / ____Type:  TIV, inactivated  LAIV, live, attenuated  
Yes, dose 4 date:____ / ____ / ____Type:  TIV, inactivated  LAIV, live, attenuated 
No If no, provide reason:   Offered at practice, but declined   Other 
reason__________ 
 Unknown/no information available 
Received flu vaccine during pregnancy?  Received flu vaccine during season 
above? 
 (0) No       (0) No 
 (1) Yes, during season of admission   (1) Yes, during pregnancy 
 (2) Yes, during last flu season   (2) Yes, after delivery 
 (9) Unknown      (3) Yes, pregnancy was last season 
 (9) Unknown 
Other vaccines: 
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 (continued) 
Any prior long-standing/chronic medical problems: (i.e. asthma, COPD, diabetes) 
Yes    No    Unknown/no information available 
 
 
 
 
 
 
 
Any medications? 
Yes    No    Unknown/no information available 
 
 
 
 
 
 
 
 
 
 
Any complications during this pregnancy: (especially conditions requiring 
hospitalization) 
Yes    No    Unknown/no information available 
 
 
 
 
 
 
 
 
 
 
Did mom ever smoke? 
Yes    No     Unknown/no information available 
 
If YES, details 
 Other information: 
 
 
 
